Zhao, Yujun

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 652

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 462

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 328

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 300

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

Zhao, Y., Liu, L., Sun, W., Lu, J., McEachern, D., Li, X., Yu, S., Bernard, D., Ochsenbein, P., Ferey, V., et al. (2013) · Journal of the American Chemical Society

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 234

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 233

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research

Protein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

Cited by 199

Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics

Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 72

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 52